Comparing protein VEGF inhibitors: In vitro biological studies.
about
Updates on the Clinical Trials in Diabetic Macular EdemaReceptor tyrosine kinase-mediated angiogenesisSYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Aflibercept for the treatment of age-related macular degeneration.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGFSystemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMDOptical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Anti-vascular endothelial growth factor therapy for diabetic macular edemaGene Therapy with Endogenous Inhibitors of Angiogenesis for Neovascular Age-Related Macular Degeneration: Beyond Anti-VEGF Therapy.Role of salivary vascular endothelial growth factor (VEGF) in palatal mucosal wound healing.Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approachGene Transfer of Prolyl Hydroxylase Domain 2 Inhibits Hypoxia-inducible Angiogenesis in a Model of Choroidal NeovascularizationBiological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.In vitro and ex vivo retina angiogenesis assays.What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.Ranibizumab: a review of its use in myopic choroidal neovascularization.Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway.Intravitreal aflibercept for neovascular age-related macular degeneration.A Critical Analysis of the Available In Vitro and Ex Vivo Methods to Study Retinal Angiogenesis.Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabComparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion.Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.Therapeutic efficacy of bevacizumab for age-related macular degeneration: what are the implications of CATT for routine management?VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema.Vascular endothelial growth factor-B: Impact on physiology and pathology.Clinical pharmacology of intravitreal anti-VEGF drugs.The study of intravitreal drug pharmacokinetics: does it matter? and if so, how?Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization
P2860
Q26767100-50AF6D7F-1C8A-42CD-9AEE-C4DFA5908C06Q27001612-1835DB8C-650D-4720-9432-C371F3625D66Q30490738-978C69B5-B273-4A23-B55B-25486F383EFBQ33939215-9A763FBE-7797-41CE-BFCD-D4CA3FA15573Q34092454-C4D91357-B8FB-4194-8C91-1CC6A4CB0EA2Q34517448-B2C00655-327D-4CDD-8CE7-B0757595449AQ34608306-2422C159-6D72-45B2-BC17-C853A90232DEQ35016867-5814A1ED-4A05-4A89-B467-CB63993ED9ACQ35064343-06345DC2-EC7C-40BE-8607-65D9A06CC3CFQ35188790-89FE6EEE-ABDF-4EFF-9620-F8FAE12512B8Q35925996-CE5E2269-06E7-40FB-946B-61F43B656965Q36220942-F39D5626-A5F1-47D2-8072-CA8B51401C01Q37635057-F0FB8090-C027-4EB2-A812-64631E331FF3Q38003860-986651E5-9546-4A44-B7A8-F9E4FD1C9D6AQ38087692-A3D2C6A7-77FD-4BAB-A2D3-0DCA051FB3F0Q38094076-D3110E3B-AB41-4EE3-8D57-A020915DA345Q38152261-53DCC81B-CF10-470D-9B67-4D8556A72B43Q38170235-A95EA8F2-C8D3-45F9-8B16-F92ED9607415Q38183850-AAA2B9C4-1885-4E42-911A-DAABE4551708Q38223928-6CFFB35B-C30B-4C76-A88E-72C92173682EQ38261105-E5D7638B-195B-448A-B343-2B9CA2D580F1Q39466620-BF5C48F4-39AD-4D69-BD2D-224D97700AFFQ41468154-241CD041-4B56-4833-9D6F-714EEBF46746Q42139247-858EBF0E-B691-4B01-B6AA-3E9AE28055CCQ42204340-8EB174A3-1CCC-44BF-93A8-D22A6ED0F314Q43580379-524EEFB7-DB47-4975-BE0C-E97EA1B974F2Q46526244-3402D7C7-366D-4E1B-A64C-940913046277Q47243737-22CE241B-81E8-467A-A667-73F9FE5AB81FQ47450318-AA283D73-DA87-466C-B545-45DDE5F982AAQ48109878-D2F630E4-2F02-4BDA-87E6-D4A43C14D86DQ49995786-5A90BD32-B94C-4775-B698-4F54E1BF39FDQ54336106-58194CB8-BE18-43FD-8901-B79CF6375799Q58747914-52D5911C-F655-4263-A4D8-2B7DAA5F3530
P2860
Comparing protein VEGF inhibitors: In vitro biological studies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Comparing protein VEGF inhibitors: In vitro biological studies.
@en
Comparing protein VEGF inhibitors: In vitro biological studies.
@nl
type
label
Comparing protein VEGF inhibitors: In vitro biological studies.
@en
Comparing protein VEGF inhibitors: In vitro biological studies.
@nl
prefLabel
Comparing protein VEGF inhibitors: In vitro biological studies.
@en
Comparing protein VEGF inhibitors: In vitro biological studies.
@nl
P2093
P1476
Comparing protein VEGF inhibitors: In vitro biological studies.
@en
P2093
Napoleone Ferrara
Xiao Huan Liang
P304
P356
10.1016/J.BBRC.2011.04.014
P407
P577
2011-04-08T00:00:00Z